EU explains criteria for issuing duplicate marketing authorisations
This article was originally published in SRA
Executive Summary
Pharmaceutical companies seeking duplicate/multiple marketing authorisations for drugs approved under the European centralised procedure can now refer to a new document issued by the European Commission that explains the criteria applied for granting such authorisations1,2.
You may also be interested in...
New EU Approach On Duplicate Marketing Authorizations Prompts Questions
The European Commission says there is no automatic link between the introduction of a duplicate marketing authorization by the holder of the original medicinal product (be it a chemical or a biological medicinal product) and the increased availability of a medicine.
New EU Approach On Duplicate Marketing Authorizations Prompts Questions
The European Commission says there is no automatic link between the introduction of a duplicate marketing authorization by the holder of the original medicinal product (be it a chemical or a biological medicinal product) and the increased availability of said medicine.
Global Medtech Guidance Tracker: September 2023
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.